Regeneron Pharmaceuticals-Licensed Olatorepatide Shows Positive Phase 3 Results for Obesity in Chinese Patients

Obesity Drug Olatorepatide, Licensed by Regeneron Pharmaceuticals, Shows Positive Phase 3 Outcomes in Chinese Patients Regeneron Pharmaceuticals, Inc. today announced Hansoh Pharmaceutical Group Company Limited has shared positive topline data from its…

Read MoreRegeneron Pharmaceuticals-Licensed Olatorepatide Shows Positive Phase 3 Results for Obesity in Chinese Patients

Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results…

Read MoreBristol Myers Squibb Reports Positive Phase 3 SUCCESSOR-2 Trial Results for Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Enhertu Receives U.S. Priority Review for Post-Neoadjuvant Treatment of HER2-Positive Early Breast Cancer

Enhertu receives U.S. Priority Review as a post-neoadjuvant therapy for patients with early-stage HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted…

Read MoreEnhertu Receives U.S. Priority Review for Post-Neoadjuvant Treatment of HER2-Positive Early Breast Cancer

AbbVie Reports Positive Topline Results from Phase 1 Multiple Ascending Dose Study of Long-Acting Amylin Analog ABBV-295 in Adults

AbbVie reports positive topline results from a Phase 1 multiple ascending dose study of ABBV-295, a long-acting amylin analog evaluated in adults. AbbVie (NYSE: ABBV) today announced positive topline results1 from…

Read MoreAbbVie Reports Positive Topline Results from Phase 1 Multiple Ascending Dose Study of Long-Acting Amylin Analog ABBV-295 in Adults

Celltrion Plans to Cancel 9.11 Million Treasury Shares to Boost Shareholder Value Amid Market Uncertainty

Celltrion Plans Cancellation of 9.11 Million Treasury Shares to Strengthen Shareholder Value Amid Market Volatility Celltrion has announced a significant corporate governance and capital management initiative aimed at strengthening shareholder…

Read MoreCelltrion Plans to Cancel 9.11 Million Treasury Shares to Boost Shareholder Value Amid Market Uncertainty